The neuroscience group at Roche Holding AG’s Genentech, Inc. won US Food and Drug Administration approval of its second drug in two weeks on 14 August when Enspryng (satralizumab-mwge) was cleared to treat adults with neuromyelitis optica spectrum disorder who are aquaporin-4 (AQP4) antibody positive. The interleukin-6 (IL-6) receptor inhibitor is the third NMOSD therapy approved since 2019, but it is the first treatment that can be administered in patients’ homes and at a price below its two competitors.
The list price for Enspryng, which is administered every four weeks by subcutaneous injection, is $14,615 per dose. That translates...
